
    
      VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra
      standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI)
      measuring the effects on the acute rise and fall of the plasma C reactive protein levels
      during the first 14 days
    
  